Skip to main content
SpringerLink
Log in

Management of Arrhythmia: Medications, Electrophysiology Studies and Ablation

  • Chapter
  • First Online:
Hypertrophic Cardiomyopathy

  • 1942 Accesses

Abstract

In patients with hypertrophic cardiomyopathy (HCM), arrhythmias including atrial fibrillation (AF), supraventricular tachycardia (SVT), and ventricular tachycardia (VT) are common. Many of these arrhythmias are asymptomatic, especially if of short duration, but some can precipitate syncope, palpitations, hemodynamic collapse or sudden cardiac death (SCD). Therefore, the evaluation of such arrhythmias, both proactively and reactively, and their clinical significance in patients with HCM is of paramount importance. In this chapter, we will discuss the incidence, diagnosis, medical management, and role of invasive testing and ablation for arrhythmias in HCM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome natural history. J Am Coll Cardiol. 2005;45:922–30.

    Article  CAS  PubMed  Google Scholar 

  2. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352:362–72.

    Article  CAS  PubMed  Google Scholar 

  3. MacRae CA, Ghaisas N, Kass S, et al. Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest. 1995;96:1216.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Gollob MH, Green MS, Tang ASL, et al. Identification of a gene responsible for familial Wolff–Parkinson–White syndrome. N Engl J Med. 2001;344:1823–31.

    Article  CAS  PubMed  Google Scholar 

  5. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, Mckenna WJ. Atrial fibrillation in hypertrophie cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279–85.

    Article  CAS  PubMed  Google Scholar 

  6. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517–24.

    Article  CAS  PubMed  Google Scholar 

  7. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:697–704.

    Article  PubMed  Google Scholar 

  8. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J. 1981;46:168–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Anderson RH, Davies MJ, Becker AE. Atrioventricular ring specialized tissue in normal heart. Eur J Cardiol. 1974;2:219–30.

    Google Scholar 

  10. Newman BJ, Donoso E, Friedberg CK. Arrhythmias in the Wolff-Parkinson-White syndrome. Prog Cardiovasc Dis. 1966;9:147–65.

    Article  CAS  PubMed  Google Scholar 

  11. Vidaillet Jr HJ, Pressley JC, Henke E, Harrell Jr FE, German LD. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med. 1987;317:65–9.

    Article  PubMed  Google Scholar 

  12. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80:1259–68.

    Article  CAS  PubMed  Google Scholar 

  13. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 1994;90:2743–7.

    Article  CAS  PubMed  Google Scholar 

  14. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981;48:252–7.

    Article  CAS  PubMed  Google Scholar 

  15. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. 1992;86:730–40.

    Article  CAS  PubMed  Google Scholar 

  16. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathyan independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873–9.

    Article  PubMed  Google Scholar 

  17. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–73.

    Article  CAS  PubMed  Google Scholar 

  18. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 1998;31:1081–5.

    Article  CAS  PubMed  Google Scholar 

  19. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol. 2006;97:1255–61.

    Article  PubMed  Google Scholar 

  20. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82:1995–2002.

    Article  CAS  PubMed  Google Scholar 

  21. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart. 2004;90:570–5.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–8.

    Article  CAS  PubMed  Google Scholar 

  24. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2001;22:1374–450.

    Article  CAS  PubMed  Google Scholar 

  25. Brembilla-Perrot B, Jacquot A, Beurrier D, Jacquemin L. Hypertrophic cardiomyopathy: Value of atrial programmed electrical stimulation in patients with or without syncope with special reference to the role of atrial arrhythmias. Int J Cardiol. 1997;59:47–56.

    Article  CAS  PubMed  Google Scholar 

  26. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 2000;31:988–98.

    Article  CAS  PubMed  Google Scholar 

  27. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–64.

    Article  PubMed  Google Scholar 

  28. Moon JCC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–4.

    Article  PubMed  Google Scholar 

  29. Marsan NA, Bax JJ. Cardiomyopathies: myocardial fibrosis assessed by CMR to predict events in HCM. Nat Rev Cardiol. 2010;7:604–6.

    Article  Google Scholar 

  30. Jaeggi ET, Gilljam T, Bauersfeld U, Chiu C, Gow R. Electrocardiographic differentiation of typical atrioventricular node reentrant tachycardia from atrioventricular reciprocating tachycardia mediated by concealed accessory pathway in children. Am J Cardiol. 2003;91:1084–9.

    Article  PubMed  Google Scholar 

  31. Klein GJ, Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1983;52:292–6.

    Article  CAS  PubMed  Google Scholar 

  32. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology. Circulation. 1999;100:886–93.

    Article  CAS  PubMed  Google Scholar 

  33. Spirito P, Bellone P, Harris KM, Bernabò P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778–85.

    Article  CAS  PubMed  Google Scholar 

  34. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420–4.

    Article  CAS  PubMed  Google Scholar 

  35. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044–51.

    Article  CAS  PubMed  Google Scholar 

  36. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–91.

    Article  CAS  PubMed  Google Scholar 

  37. Kowey PR, Eisenberg R, Engel TR. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. N Engl J Med. 1984;310:1566–9.

    Article  CAS  PubMed  Google Scholar 

  38. Massumi RA. Familial Wolff-Parkinson-White syndrome with cardiomyopathy. Am J Med. 1967;43:951–5.

    Article  CAS  PubMed  Google Scholar 

  39. Khair GZ, Soni JS, Bamrah VS. Syncope in hypertrophic cardiomyopathy. II. Coexistence of atrioventricular block and Wolff-Parkinson-White syndrome. Am Heart J. 1985;110:1083–6.

    Article  CAS  PubMed  Google Scholar 

  40. Westlake RE, Cohen W, Willis WH. Wolff-Parkinson-White syndrome and familial cardiomegaly. Am Heart J. 1962;64:314–20.

    Article  CAS  PubMed  Google Scholar 

  41. Calkins H, Sousa J, El-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med. 1991;324:1612–8.

    Article  CAS  PubMed  Google Scholar 

  42. Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome results of a prospective long-term electrophysiological follow-Up study. Circulation. 2012;125:661–8.

    Article  PubMed  Google Scholar 

  43. Fuster V. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)(vol 114, pg e257, 2006). Circulation 2007;116:E138-E.

    Google Scholar 

  44. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:2703–38.

    Article  PubMed  Google Scholar 

  45. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–85.

    Article  CAS  PubMed  Google Scholar 

  46. Hematpour K, Steinberg JS. Treatment of atrial fibrillation in hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. 2006;6:44–8.

    PubMed  Google Scholar 

  47. Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381–91.

    Article  CAS  PubMed  Google Scholar 

  48. Adam SS, McDuffie JR, Ortel TL, Williams JW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism a systematic review. Ann Intern Med. 2012;157:796–807.

    Article  PubMed  Google Scholar 

  49. Ntaios G, Papavasileiou V, Diener H-C, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298–304.

    Article  CAS  PubMed  Google Scholar 

  50. Liu X, Ouyang F, Mavrakis H, et al. Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Europace. 2005;7:421–7.

    Article  PubMed  Google Scholar 

  51. Bunch TJ, Munger TM, Friedman PA, et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19:1009–14.

    Article  PubMed  Google Scholar 

  52. Di Donna P, Olivotto I, Delcrè SDL, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace. 2010;12:347–55.

    Article  PubMed  Google Scholar 

  53. Kilicaslan F, Verma A, Saad E, et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2006;3:275–80.

    Article  PubMed  Google Scholar 

  54. Burkhardt JD, Natale A. New technologies in atrial fibrillation ablation. Circulation. 2009;120:1533–41.

    Article  PubMed  Google Scholar 

  55. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61:1713–23.

    Article  PubMed  Google Scholar 

  56. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.

    Article  CAS  PubMed  Google Scholar 

  57. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart. 1998;79:331–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53:412–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices—summary article a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol. 2002;40:1703–19.

    Article  PubMed  Google Scholar 

  60. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation. 1997;96:1525–31.

    Article  CAS  PubMed  Google Scholar 

  61. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247–346.

    Article  PubMed  Google Scholar 

  62. Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. Heart Rhythm. 2010;7:1036–42.

    Article  PubMed  Google Scholar 

  63. Rodriguez LUZ, Smeets JLRM, Timmermans C, et al. Radiofrequency catheter ablation of sustained monomorphic ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 1997;8:803–6.

    Article  CAS  PubMed  Google Scholar 

  64. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009;20:445–7.

    Article  PubMed  Google Scholar 

  65. Dukkipati SR, d’Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4:185–94.

    Article  PubMed  Google Scholar 

  66. Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22:41–8.

    Article  PubMed  Google Scholar 

  67. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.

    Article  PubMed  Google Scholar 

  68. Kwon DH, Setser RM, Popović ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24:617–25.

    Article  PubMed  Google Scholar 

  69. Bordignon S, Chun KJ, Schmidt B. Epicardial ablation of monomorphic ventricular tachycardia storm in hypertrophic cardiomyopathy. Europace. 2013;15:346.

    Article  PubMed  Google Scholar 

  70. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Catheter ablation of ventricular tachycardia. Am Heart J. 1994;127:1126–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Division of Cardiology, Stony Brook Medical School, Winthrop-University Hospital, 120 Mineola Boulevard, Suite 500, Mineola, NY, 11501, USA

    Daniel R. Zakhary MD, PhD & Joseph J. Germano DO, FACC

  2. Harvard Medical School, Boston, MA, USA

    Mark E. Josephson MD, FACC

  3. Department of Medicine and Division of Cardiology, Harvard-Thorndike Electrophysiology Institute and Arrhythmia Service, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Mark E. Josephson MD, FACC

  4. Department of Medicine and Division of Cardiology, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Baker 4, Boston, MA, 02215, USA

    Mark E. Josephson MD, FACC

Authors
  1. Daniel R. Zakhary MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph J. Germano DO, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark E. Josephson MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph J. Germano DO, FACC .

Editor information

Editors and Affiliations

  1. Winthrop University Hospital, Mineola, New York, USA

    Srihari S. Naidu

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Zakhary, D.R., Germano, J.J., Josephson, M.E. (2015). Management of Arrhythmia: Medications, Electrophysiology Studies and Ablation. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, London. https://doi.org/10.1007/978-1-4471-4956-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4956-9_16

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4955-2

  • Online ISBN: 978-1-4471-4956-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation